v3.25.2
Segment Reporting (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Mar. 31, 2025
 [1]
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Segment Reporting Information [Line Items]          
Revenues   $ 20,000 $ 39,990 $ 63,000
Total research and development expense 677,332   394,484 1,675,554 1,009,001
Advisory fee   11,737,806
Legal and accounting 520,364   590,984 1,477,909 1,155,338
Employee Expenses 163,887   334,160 145,724
Debt issuance and deferred offering costs amortization 192,249   111,793 360,200 111,793
Investor relations 226,766   771,073 6,663
Share based compensation 3,526,076 $ 17,397,774 [2] 20,923,850
Other general and administrative expense 593,609   205,860 728,514 466,084
Interest expense - related parties' loans 48,750   1,171,963 357,672 2,559,456
Loss on extinguishment of Bridge loan - related party   (2,069,923) (2,069,923)
Interest income (28,725)   2,069,923 (80,424)
Other income (240,138)   (240,138)
Net loss (5,680,170) $ (32,326,016) [3] (4,522,006) (38,006,186) (7,460,982)
NEO100 [Member]          
Segment Reporting Information [Line Items]          
Total research and development expense 109,166   98,399 688,628 456,721
NEO100-02 [Member]          
Segment Reporting Information [Line Items]          
Total research and development expense 93,326   96,367 201,787 123,431
NEO212 [Member]          
Segment Reporting Information [Line Items]          
Total research and development expense 279,074   197,962 455,629 359,696
Pediatric [Member]          
Segment Reporting Information [Line Items]          
Total research and development expense 50,178   1,591 99,010 68,988
Laboratory [Member]          
Segment Reporting Information [Line Items]          
Total research and development expense 107,465   192,377
Other [Member]          
Segment Reporting Information [Line Items]          
Total research and development expense $ 38,123   $ 165 $ 38,123 $ 165
[1] Also restated as presented in Note 7 to the condensed consolidated financial statements for the three months ended March 31, 2025
[2] Also restated as presented in Note 8 to the condensed consolidated financial statements for the three months ended March 31, 2025
[3] Also restated as presented in Note 1 to the condensed consolidated financial statements for the three months ended March 31, 2025